Nesteggg Accounting

  • Home
  • Services
    • Nesteggg Accounting
      • Payroll Services
      • Cannabis Accounting
    • Egggsact Tax, Inc.
    • Forms
      • Free Accounting Analysis
      • Business Services Agreement
      • New Corporation/LLC Request
      • New Account Setup
  • Contact Us

Congress’ Hearing Questions the Dilemma of Research

WASHINGTON, D.C. — Although federal cannabis legalization may not be imminent, Congress is taking early steps to better understand how to research and regulate the complex plant.

Research on cannabis is stuck in a Catch-22

The Health subcommittee of the U.S. House Committee on Energy and Commerce on Wednesday, Jan. 15 joined the shortlist of subcommittees that have delved into cannabis. No votes were cast, nor policy decisions made, but the Committee did address questions about how cannabis is researched, possessed and consumed.

Cannabis remains a Schedule I substance — the most restrictive class and identified as having no medical use — resulting in a lack of comprehensive research. Research is hindered because of the Schedule I classification.

“The federal government has hidden behind that Catch-22 for a long, long time,” said Representative Joe Kennedy III, a Democrat from Massachusetts.

The University of Mississippi remains the sole supplier of research-grade cannabis for federally approved trials, and the cannabis that’s available for research has been assailed by scientists as “sub-par” material that does not accurately represent the diverse array of products — and potencies — available for sale in states that have legalized recreational cannabis.

Matthew Strait, senior policy adviser for the DEA’s Diversion Control Division, said the agency has sought to remove barriers to research and is moving “expeditiously” to craft additional regulations and expand the number of licensed cultivators.

The FDA’s ongoing review of the wildly popular cannabis compound cannabidiol (CBD) remains ongoing, said Dr. Douglas Throckmorton, deputy director for regulatory programs at the FDA’s Center for Drug Evaluation of Research. He indicated his agency is evaluating research to determine CBD’s safety and efficacy, weighing non-drug pathways for compounds derived from federally legal hemp and creating avenues for new drug development involving cannabis compounds.

During their questioning, subcommittee members referenced several of the active cannabis-related bills before Congress and asked if rescheduling or even de-scheduling cannabis would solve some of these ongoing conflicts.

The House Revisits Legalization

The House of Representatives continues to keep the discussion of legal cannabis alive. Wednesday, January 15th the Energy and Commerce Subcommittee on Health will discuss measures, which include several proposals aimed at promoting research into cannabis. But while advocates view the development as a positive step, there are some concerns about the fact that only officials from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA) and National Institute on Drug Abuse (NIDA) were invited to testify.

The House keeps the discussion alive

Among the legislation being discussed will be proposed bills addressing the use of medical marijuana, research, the removal of cannabis from the schedule of controlled substances, and investment in communities adversely affected by the war on drugs. You can follow the links below to read what each bill proposes.

H.R. 601, the “Medical Cannabis Research Act of 2019”

H.R. 171, the “Legitimate Use of Medicinal Marihuana Act” or the “LUMMA”

H.R. 1151, the “Veterans Medical Marijuana Safe Harbor Act”

H.R. 2843, the “Marijuana Freedom and Opportunity Act”

H.R. 3797, the “Medical Marijuana Research Act of 2019”

H.R. 3884, the “Marijuana Opportunity Reinvestment and Expungement Act of 2019” or the “MORE

Recent Posts

  • Economy Opening… Stop… Start…
  • Road Map to Opening
  • Tried Calling?
  • Free Credit Reports
  • CA License Extensions for Cannabis Business
  • What Are Libraries Doing Now
  • Cannabis Markup to Remain the 80%
  • Time to Retire?

Archives

  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018

Categories

  • Cannabis Compliant Accounting + Tax
  • NestEggg's Small Business HELP
  • News
  • Uncategorized

Stay Connected

Nesteggg Facebook

The Nesteggg Group ©2019
All Rights Reserved

Get in Touch

1127 St. Paul Ave
Tacoma WA 98421

1-(888) 987-NEST

accounting@nesteggg.com

Web Design & Maintenance by AquaZebra

constant contact

Copyright © 2023 · Executive Pro Theme on Genesis Framework · WordPress · Log in